GO:0004361 glutaryl-CoA dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004361 (glutaryl-CoA dehydrogenase activity) catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA, transferring electrons to electron-transfer flavoprotein.
• The reaction is a committed step in lysine and tryptophan degradation and is essential for mitochondrial energy metabolism.
• Biallelic pathogenic variants in GCDH cause glutaric aciduria type 1 (GA1), a neurometabolic disorder with striatal injury.
• GCDH is emerging as a tumor suppressor in hepatocellular carcinoma and a prognostic biomarker in pancreatic cancer.
• SIRT5-mediated deglutarylation of GCDH regulates lysine oxidation and metabolic flux in mice.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable mechanistic and therapeutic studies of GCDH.
Description
Glutaryl-CoA dehydrogenase (GCDH) is a mitochondrial flavoenzyme that catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA, a key step in the degradation of lysine, hydroxylysine, and tryptophan. This reaction, annotated as GO:0004361, couples substrate oxidation to the reduction of electron-transfer flavoprotein (ETF), feeding electrons into the respiratory chain. GCDH deficiency is the biochemical hallmark of glutaric aciduria type 1 (GA1), an autosomal recessive neurometabolic disorder characterized by striatal degeneration and dystonia. Beyond GA1, recent studies have implicated GCDH in cancer biology, where its expression suppresses tumor progression in hepatocellular carcinoma and influences metastasis and prognosis. Understanding the molecular mechanism, regulation, and disease relevance of GO:0004361 is therefore critical for both inherited metabolic disorders and oncology research.
glutaryl-CoA dehydrogenase activity At A Glance
| GO ID | GO:0004361 |
|---|---|
| GO term | glutaryl-CoA dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | glutaryl coenzyme A dehydrogenase activity |
| Major function | Oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA with electron transfer to ETF |
| Reaction | glutaryl-CoA + 2 H+ + oxidized ETF = (2E)-butenoyl-CoA + CO2 + reduced ETF |
| Cofactor | FAD (flavin adenine dinucleotide) |
| Subcellular location | Mitochondrial matrix |
| Pathway | Lysine and tryptophan degradation |
What Is GO:0004361?
GO:0004361, glutaryl-CoA dehydrogenase activity, is a molecular function defined as the catalysis of the reaction: glutaryl-CoA + 2 H+ + oxidized [electron-transfer flavoprotein] = (2E)-butenoyl-CoA + CO2 + reduced [electron-transfer flavoprotein]. In simpler terms, it is the enzyme activity that removes a carboxyl group from glutaryl-CoA while transferring electrons to ETF, producing crotonyl-CoA and CO2.
Why Is glutaryl-CoA dehydrogenase activity Important in Cell Biology?
GO:0004361 is essential for mitochondrial energy metabolism and lysine catabolism, and its dysfunction leads to the accumulation of neurotoxic metabolites such as glutaric acid and 3-hydroxyglutaric acid, which are central to the pathogenesis of GA1. Moreover, GCDH has been identified as a tumor suppressor in hepatocellular carcinoma and a biomarker linked to metastasis and prognosis in pancreatic cancer, highlighting its broader significance in cancer metabolism.
• Deficiency causes glutaric aciduria type 1, a devastating neurometabolic disorder.
• GCDH suppresses tumor progression in hepatocellular carcinoma.
• GCDH expression correlates with metastasis and prognosis in pancreatic cancer.
• SIRT5-mediated deglutarylation regulates GCDH activity and lysine oxidation.
• GCDH deficiency leads to neuromotor and cognitive impairment in mouse models.
• The enzyme is a target for newborn screening and dietary therapy in GA1.
• GCDH misfolding is a key pathogenic mechanism in GA1.
• Genotype-phenotype correlations in GA1 inform clinical management.
• GCDH links lysine degradation to NF-KB signaling in cancer.
• GO:0004361 is a model for studying mitochondrial flavoenzyme mechanisms.
What Happens During glutaryl-CoA dehydrogenase activity?
Substrate binding and FAD reduction
In simple terms: The enzyme grabs glutaryl-CoA and pulls electrons off it.
GCDH binds glutaryl-CoA in its active site, where the FAD cofactor is reduced as the substrate is oxidized. This step initiates the decarboxylation reaction.
Oxidative decarboxylation
In simple terms: A carboxyl group is removed as CO2.
Following FAD reduction, the substrate undergoes decarboxylation, releasing CO2 and forming a crotonyl-CoA intermediate.
Electron transfer to ETF
In simple terms: Electrons are handed off to a carrier protein.
Reduced FAD transfers electrons to oxidized electron-transfer flavoprotein (ETF), regenerating the enzyme for another catalytic cycle.
Product release
In simple terms: The final product crotonyl-CoA is released.
The reaction yields (2E)-butenoyl-CoA (crotonyl-CoA), which can enter further metabolic pathways, and reduced ETF, which feeds electrons into the respiratory chain.
Key Genes Involved in GO:0004361 glutaryl-CoA dehydrogenase activity
The following genes and proteins are directly involved in or regulate glutaryl-CoA dehydrogenase activity and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCDH | Encodes glutaryl-CoA dehydrogenase, the enzyme catalyzing GO:0004361 | Mutations cause GA1; tumor suppressor in HCC |
| ETFA | Electron-transfer flavoprotein alpha subunit, accepts electrons from GCDH | Defects cause GA2; interacts with GCDH |
| ETFB | Electron-transfer flavoprotein beta subunit, part of ETF complex | Defects cause GA2; required for GCDH activity |
| ETFDH | Electron-transfer flavoprotein dehydrogenase, transfers electrons to CoQ | Defects cause GA2; links GCDH to respiratory chain |
| SIRT5 | NAD+-dependent desuccinylase/deglutarylase that removes glutaryl groups from GCDH | Regulates GCDH activity and lysine oxidation |
| NFKB1 | NF-KB signaling pathway component linked to GCDH-mediated metastasis | GCDH affects NF-KB signaling in HCC |
| ACAT2 | Acetyl-CoA acetyltransferase 2, involved in cholesterol metabolism | GCDH-driven crotonylation dysregulates ACAT2 in pancreatic cancer |
| HADHA | Mitochondrial trifunctional protein subunit, involved in fatty acid oxidation | Potential metabolic interplay with GCDH |
| HADHB | Mitochondrial trifunctional protein subunit | Potential metabolic interplay with GCDH |
| CPT2 | Carnitine palmitoyltransferase 2, fatty acid oxidation | Secondary metabolic effects in GA1 |
| SLC25A13 | Aspartate/glutamate carrier, mitochondrial | May influence glutaryl-CoA levels |
| GLUD1 | Glutamate dehydrogenase 1, links amino acid metabolism | Potential cross-talk with lysine degradation |
| AASS | Alpha-aminoadipic semialdehyde synthase, lysine degradation | Upstream of GCDH in lysine catabolism |
| DHTKD1 | Dehydrogenase E1 and transketolase domain containing 1 | Involved in 2-aminoadipic acid metabolism |
| PCCA | Propionyl-CoA carboxylase alpha subunit | Related to organic acidemias |
| PCCB | Propionyl-CoA carboxylase beta subunit | Related to organic acidemias |
| SLC22A5 | Carnitine transporter, affects mitochondrial fatty acid oxidation | Modifies metabolic phenotype in GA1 |
| PPARGC1A | PGC-1alpha, mitochondrial biogenesis regulator | May regulate GCDH expression |
How Is glutaryl-CoA dehydrogenase activity Regulated?
GCDH activity is regulated at multiple levels. SIRT5-mediated deglutarylation of GCDH promotes lysine oxidation in mice, indicating post-translational control. Additionally, GCDH expression is influenced by metabolic state and may be subject to regulation by transcription factors such as PGC-1alpha, although direct evidence in the context of GO:0004361 is limited.
glutaryl-CoA dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCDH | Glutaric aciduria type 1 | Gcdh-/- mouse, patient fibroblasts |
| GCDH | Hepatocellular carcinoma | HCC cell lines with GCDH knockout/overexpression |
| GCDH | Pancreatic cancer | Pancreatic cancer cells with GCDH knockdown |
| SIRT5 | Lysine oxidation regulation | Sirt5-/- mouse, GCDH mutant cells |
| ETFA/ETFB/ETFDH | Glutaric aciduria type 2 | Patient-derived fibroblasts, KO cell lines |
Glutaric aciduria type 1 (GA1)
Biallelic pathogenic variants in GCDH cause GA1, an autosomal recessive disorder characterized by striatal degeneration, dystonia, and encephalopathic crises. The accumulation of glutaric acid and 3-hydroxyglutaric acid due to deficient GCDH activity is neurotoxic. Newborn screening and dietary therapy can improve outcomes.
Hepatocellular carcinoma (HCC)
GCDH suppresses tumor progression and shapes an anti-tumor microenvironment in HCC. Loss of GCDH expression is associated with poor prognosis, and its restoration inhibits tumor growth. GCDH also links lysine degradation to HCC metastasis via NF-KB signaling.
Pancreatic cancer
Targeting GCDH-driven acetyl-CoA acetyltransferase 2 crotonylation dysregulates cholesterol metabolism in pancreatic cancer cells, suggesting GCDH as a metabolic vulnerability.
Neurodegeneration
GCDH-deficient mice exhibit impairment of neuromotor development and cognition associated with histopathological and neurochemical abnormalities in the cerebral cortex and striatum, modeling GA1 neuropathology.
From glutaryl-CoA dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GCDH loss cause metabolic and neuropathological changes? | Gcdh-/- knockout mouse |
| How do GA1-associated point mutations affect GCDH stability? | Point-mutation knock-in cell lines |
| Can wild-type GCDH rescue GA1 phenotypes? | Knock-in of wild-type GCDH in patient cells |
| Where is GCDH localized in mitochondria? | Tagged knock-in with fluorescent tag |
| Does GCDH overexpression suppress tumor growth? | Overexpression in HCC cell lines |
| How does SIRT5 regulate GCDH? | SIRT5 knockout and GCDH mutant models |
How to Study the glutaryl-CoA dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | GCDH catalytic activity | Diagnosis of GA1, kinetic studies |
| RNA-seq | GCDH mRNA expression | Cancer profiling, genotype-phenotype |
| Whole-exome sequencing | GCDH mutations | Genetic diagnosis of GA1 |
| Mass spectrometry | Glutarylation of GCDH | SIRT5 regulation studies |
| Metabolomics | Glutaric acid levels | Newborn screening, mouse phenotyping |
| Immunohistochemistry | GCDH protein expression | Tumor tissue analysis |
| CRISPR screening | Genes affecting GCDH dependency | Cancer cell line fitness |
| Mitochondrial respiration assay | Electron transfer to ETF | Functional validation of GCDH variants |
Enzyme activity assays
GCDH activity can be measured spectrophotometrically by monitoring the reduction of electron-transfer flavoprotein (ETF) or using substrate analogs. These assays are essential for diagnosing GA1 and studying enzyme kinetics.
Genomic and transcriptomic analysis
RNA-seq and whole-exome sequencing identify GCDH mutations and expression changes in patient samples and cancer cell lines.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics detects glutarylation and other modifications on GCDH, revealing regulation by SIRT5.
Metabolomics
Quantification of glutaric acid, 3-hydroxyglutaric acid, and other metabolites in body fluids or cell extracts assesses GCDH function in vivo.
How CRISPR Can Be Used to Study GO:0004361 glutaryl-CoA dehydrogenase activity
Knockout
CRISPR knockout of GCDH in cell lines and mouse models recapitulates GA1 biochemical features and has been used to demonstrate tumor suppressor function in HCC.
Point Mutation
Introducing GA1-associated point mutations (e.g., p.Arg402Trp) into GCDH via CRISPR allows study of protein misfolding and loss of function.
Knock-in
Knock-in of wild-type or tagged GCDH enables rescue experiments and localization studies in patient-derived cells.
Overexpression
CRISPR activation or lentiviral overexpression of GCDH is used to assess its effects on tumor growth and metabolism.
How EDITGENE Supports glutaryl-CoA dehydrogenase activity Research
Researchers studying glutaryl-CoA dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or oncogenic phenotypes. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for glutaryl-CoA dehydrogenase activity research.
Frequently Asked Questions About glutaryl-CoA dehydrogenase activity
What is glutaryl-CoA dehydrogenase activity?
It is the enzyme activity (GO:0004361) that catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA, transferring electrons to electron-transfer flavoprotein.
What genes are involved in glutaryl-CoA dehydrogenase activity?
The primary gene is GCDH, which encodes the enzyme. Other genes such as ETFA, ETFB, ETFDH, and SIRT5 modulate its function.
What diseases are associated with glutaryl-CoA dehydrogenase deficiency?
Deficiency causes glutaric aciduria type 1, a neurometabolic disorder. GCDH is also implicated in hepatocellular carcinoma and pancreatic cancer.
How is glutaryl-CoA dehydrogenase activity regulated?
It is regulated by post-translational modification, notably deglutarylation by SIRT5, and by metabolic state.
What is the reaction catalyzed by glutaryl-CoA dehydrogenase?
Glutaryl-CoA + 2 H+ + oxidized ETF = (2E)-butenoyl-CoA + CO2 + reduced ETF.
What are the symptoms of glutaric aciduria type 1?
Symptoms include macrocephaly, dystonia, and striatal degeneration, often triggered by catabolic stress.
Can CRISPR be used to model glutaryl-CoA dehydrogenase deficiency?
Yes, CRISPR knockout of GCDH in cells and mice recapitulates key features of GA1 and has been used in cancer research.
What is the role of GCDH in cancer?
GCDH acts as a tumor suppressor in hepatocellular carcinoma and its expression correlates with prognosis in pancreatic cancer.
How is glutaryl-CoA dehydrogenase activity measured?
It is measured by enzyme assays monitoring ETF reduction or by metabolomic quantification of glutaric acid.
What are the treatment options for GA1?
Treatment includes dietary lysine restriction, carnitine supplementation, and emergency management during catabolic crises.
Conclusion
GO:0004361, glutaryl-CoA dehydrogenase activity, is a critical mitochondrial enzyme function with profound implications for inherited metabolic disease and cancer. Its study continues to reveal new insights into lysine degradation, metabolic regulation, and tumor biology. EDITGENE provides the tools to dissect these mechanisms with precision.
References
- 1. Lao Y et al.. 2024. Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.. J Hepatol 81(5):847-861 PMID: 38825017
- 2. Boy N et al.. 2023. Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.. J Inherit Metab Dis 46(3):482-519 PMID: 36221165
- 3. Barroso M et al.. 2023. Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1.. Int J Mol Sci 24(17) PMID: 37685964
- 4. Schuurmans IME et al.. 2023. Exploring genotype-phenotype correlations in glutaric aciduria type 1.. J Inherit Metab Dis 46(3):371-390 PMID: 37020324
- 5. Bhatt DP et al.. 2022. Deglutarylation of glutaryl-CoA dehydrogenase by deacylating enzyme SIRT5 promotes lysine oxidation in mice.. J Biol Chem 298(4):101723 PMID: 35157847
- 6. Hu Q et al.. 2025. Glutaryl-CoA dehydrogenase: a key biomarker linking lysine degradation to hepatocellular carcinoma metastasis and prognosis via NF-KB signaling pathway.. J Gastrointest Oncol 16(6):2719-2730 PMID: 41522757
- 7. Castro ET et al.. 2024. Impairment of neuromotor development and cognition associated with histopathological and neurochemical abnormalities in the cerebral cortex and striatum of glutaryl-CoA dehydrogenase deficient mice.. Neurochem Int 181:105898 PMID: 39522695
- 8. Han F et al.. 2026. Targeting glutaryl-CoA dehydrogenase-driven acetyl coenzyme A acetyltransferase 2 crotonylation dysregulates cholesterol metabolism in pancreatic cancer cells.. Int J Biol Macromol 335(Pt 2):149182 PMID: 41285334
